Division of Infectious Diseases, Department of Paediatrics, Transplant and Regenerative Medicine Center, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Pediatric Infectious Diseases Unit and Laboratory of Virology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Pediatr Transplant. 2024 Aug;28(5):e14781. doi: 10.1111/petr.14781.
The International Pediatric Transplant Association convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders (PTLD) after pediatric solid organ transplantation. This report addresses the outcomes of deliberations by the PTLD Management Working Group. A strong recommendation was made for reduction in immunosuppression as the first step in management. Similarly, strong recommendations were made for the use of the anti-CD20 monoclonal antibody (rituximab) as was the case for chemotherapy in selected scenarios. In some scenarios, there is uncoupling of the strength of the recommendations from the available evidence in situations where such evidence is lacking but collective clinical experiences drive decision-making. Of note, there are no large, randomized phase III trials of any treatment for PTLD in the pediatric age group. Current gaps and future research priorities are highlighted.
国际儿科移植协会召开了一次专家共识会议,评估了目前与儿科实体器官移植后移植后淋巴增殖性疾病(PTLD)相关的各种护理方面的证据,并提出了建议。本报告介绍了 PTLD 管理工作组审议的结果。强烈建议减少免疫抑制作为管理的第一步。同样,强烈建议使用抗 CD20 单克隆抗体(利妥昔单抗),就像在某些情况下使用化疗一样。在某些情况下,在缺乏此类证据的情况下,建议的力度与可用证据之间存在脱节,但集体临床经验推动了决策。值得注意的是,在儿科年龄组中,没有针对任何 PTLD 治疗的大型、随机 III 期试验。突出了当前的差距和未来的研究重点。